Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 190 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cerebrospinal Fluid Clear all

Conditions: Parkinson Disease, Cerebrospinal Fluid
Interventions: N-Acetylcysteine, Lumbar Puncture, Fluoroscopy; Drug · Procedure · Radiation
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Ocrelizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Dimethyl Fumarate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: St Louis, Missouri • Seattle, Washington

Conditions: Postdural Puncture Headache, Post-Lumbar Puncture Headache, Cerebrospinal Fluid Leaks
Interventions: Morphine, Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Subjects
Interventions: PF-06648671, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Hydrocephalus
Interventions: Thermal Anisotropy; Device
Lead sponsor: Rhaeos, Inc.; Industry
Eligibility: 5 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Meningitis
Interventions: Daptomycin; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Blood Draw, Lumbar Puncture; Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy, Seizures
Interventions: Perampanel; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: HIV
Interventions: Raltegravir, Efavirenz; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Alzheimer Disease
Interventions: Lovostatin, Ibuprofen; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Central Nervous System Infection
Interventions: Delve Detect CSF mNGS Test, Real-World Data; Diagnostic Test · Other
Lead sponsor: Delve Bio, Inc.; Industry
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 3 more

Conditions: Brain and Central Nervous System Tumors
Interventions: Not listed
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Healthy Subjects, Magnetic Resonance Imaging, Central Nervous System, Volunteer, Neurological Disorder
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 35 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: antitumor drug screening assay; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Skull Base Neoplasms, Cerebrospinal Fluid Leakage, Nasal; Hypertrophy, Mucous Membrane (Septum)
Interventions: Non-Absorbable Packing (Silastic Splint), PuraGel (RADA16) Hydrogel; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Subarachnoid Hemorrhage, Cerebral Vasospasm, Hydrocephalus
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Hydrocephalus
Interventions: Rhaeos Shunt Monitoring System (RSMS), ShuntCheck III; Device
Lead sponsor: Rhaeos, Inc.; Industry
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: raltegravir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: ABT-384; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Back Pain
Interventions: Myelogram; Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hydrocephalus
Interventions: FlowSense; Device
Lead sponsor: Rhaeos, Inc.; Industry
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Tampa, Florida • Chicago, Illinois • Rolling Meadows, Illinois

Conditions: Post-hemorrhagic Hydrocephalus (PHH)
Interventions: fCTOT cap, NIRF planar imaging, ICG; Device · Drug
Lead sponsor: Eva Sevick; Other
Eligibility: Up to 6 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Incidence of Headache Following an Unintentional Dural Puncture

A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)

Formative Usability Assessment of Wireless Thermal Anisotropy Devices

Cerebrospinal Fluid Pharmacokinetics of Daptomycin

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)

Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease

Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection

Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors

Studying Motor Neuron Tests

Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer

Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery

Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage

A Prospective Study Comparing CSF Shunt Flow Between "Virtual Off" and "Flow Permissive" Shunt Valve Settings Using a Wireless, Noninvasive Shunt Flow Sensor

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid

Measure of Cerebrospinal Fluid (CSF) Pressure Variation With Patient Positioning

Flow Measurements in Functional CSF Shunts and Off-Shunt Locations with a Second-Generation Thermal Device

Assessing CSF Flow Dynamics in Pediatric Hemorrhagic Hydrocephalus